Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2017-09-20
Target enrollment:
Participant gender:
Summary
A Phase I/IIa, open-label, uncontrolled study to evaluate the safety and efficacy of
Astarabine (BST-236) as single agent in patients with refractory or relapsed Acute Myeloid
Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) disease